VitaNova Life Sciences (VNOV) Receivables - Net (2024 - 2026)

VitaNova Life Sciences has disclosed Receivables - Net across 3 years of filings, most recently posting $378237.0 for Q3 2026.

• Receivables - Net for Q3 2026 came in at $378237.0, down 62.71% year-over-year; the trailing twelve-month figure through Jul 2026 was $378237.0 (down 62.71% YoY), and the FY2026 annual result was $788109.0, down 37.79% from the prior year.
• Receivables - Net for Q3 2026 stood at $378237.0, down from $788109.0 in the prior quarter.
• Across five years, Receivables - Net topped out at $1.3 million in Q2 2025 and bottomed at $54018.0 in Q1 2025.
• Average Receivables - Net over 3 years is $680793.9, with a median of $835360.5 recorded in 2025.
• On a YoY basis, Receivables - Net climbed as much as 1759.46% in 2026 and fell as far as 62.71% in 2026.
• Year by year, Receivables - Net stood at $57700.0 in 2024, then soared by 1429.66% to $882612.0 in 2025, then sank by 57.15% to $378237.0 in 2026.
• The last three Receivables - Net figures came in at $378237.0 (Q3 2026), $788109.0 (Q2 2026), and $1.0 million (Q1 2026), per Business Quant data.